Results 151 to 160 of about 67,843 (252)

Evaluating Whole Fruit Feijoa Powder for Type 2 Diabetes Risk Prevention: A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Low energy diets (LEDs) are effective for body weight (BW) loss and improvement of type 2 diabetes (T2D) risk biomarkers. Emerging evidence suggests that whole fruit feijoa powder, rich in polyphenols and abscisic acid, may further support T2D prevention.
I. A. Mohamed, I. R. Sequeira‐Bisson, J. J. Lim, L. D. Plank, R. Murphy, S. D. Poppitt, J. L. Miles‐Chan   +6 more
wiley   +1 more source

Configurational diversity of metabotropic glutamate receptor complexes with beta-arrestins. [PDF]

Nat Commun
Marx DC, Gonzalez-Hernandez AJ, Lee J, Siepe D, Weber WF, Huynh K, Gallo PN, Sharghi Moshtaghin S, Arefin A, Broichhagen J, Kalocsay M, Eliezer D, Levitz J.   +12 more
europepmc   +1 more source

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek, Hajnalka Lőrincz, Mariann Harangi, Attila Csaba Nagy   +3 more
wiley   +1 more source

ALOX15 mediates thrombin‐induced myristoylation, trafficking, and interaction of protease‐activated receptors, leading to platelet activation and hemostasis

The FEBS Journal, EarlyView.
The role of PARs in platelet function is fairly known; however, the underlying mechanisms are not fully understood. We report that thrombin myristoylates PAR4 in mouse platelets and PAR1 and PAR4 in human platelets, facilitating their membrane transport and interaction, leading to PAR3/4 heterodimers in mice and PAR1/4 heterodimers in humans.
Suresh Govatati, Chandra Sekhar Yadavalli, Md Monirul Hoque, Swapna Thota, Gadiparthi N. Rao   +4 more
wiley   +1 more source

G Protein-Mediated Allosteric Modulation of Ligand Binding in Class A GPCRs: Receptor-Ligand-Transducer Ensembles in Disease and Drug Discovery. [PDF]

Pharmaceuticals (Basel)
Kurihara Y, Kurihara H.
europepmc   +1 more source

ALOX15 links lipid metabolism to receptor trafficking in platelet activation

The FEBS Journal, EarlyView.
This schematic summarizes known and newly identified mechanisms of thrombin‐mediated platelet activation. In addition to classical thrombin‐induced PAR4 signaling pathways, thrombin activates an ALOX15–HETE–PKCθ–NMT1 signaling cascade that promotes protein myristoylation, facilitates receptor trafficking, and enhances PAR4 surface expression on ...
Yosef Eshetie Amare, Sharad Saxena, Serena Zacchigna   +2 more
wiley   +1 more source

On the generalization and usability of cofolding models for GPCR drug discovery. [PDF]

NPJ Drug Discov
Zhang L, Friesner RA, Miller EB, Glm Rodrigues JP.   +3 more
europepmc   +1 more source

Linagliptin increases the expression of LRP2 independent of Nrf2 in streptozotocin‐induced diabetic mice

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Oxidative stress is thought to play a role in the onset and progression of diabetic nephropathy (DN). Nuclear factor erythroid‐related factor 2 (Nrf2) is a master regulator of antioxidant and detoxification pathways and provides cellular protection against oxidative stress.
Suratsawadee Promsuwan, Yumi Takiyama, Takao Takiyama, Yuri Takiyama, Hiroya Kitsunai, Hiroshi Nomoto   +5 more
wiley   +1 more source

Targeting tumor-associated G-protein coupled receptors: beyond single-axis inhibition toward multidimensional regulation. [PDF]

Cell Oncol (Dordr)
Zhou X, Tan B, Zhang T, Liu W, Zuo Y, Ren B, Wang T, Li L, Chen S, Lu J.   +9 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source